|
|
|
|
|
|
|
M T Wed Th F |
|
9 September, 2026 |
|
|
sponsored by
|
|
|
|
Stop Searching Through COAs and Batch Records. Start Asking Them Questions.
|
| Katalyze digitizes COAs, paper batch records, and PDFs, then creates an ontology tailored to your operation and builds a knowledge graph connecting those records with relevant system data. Your teams can search that knowledge and ask questions in plain language, with every answer traceable to its original source. Built for GxP environments, Katalyze puts fragmented records to work across Yield Optimization, Deviation Investigation, and Raw Material Characterization, with your experts in control. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Today's Lasker Award win by the scientists who uncovered key connections between narcolepsy and orexin reminded me that the field is getting hot. Max Bayer a few months back had a good read on what's ahead for the orexin market. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Zachary Brennan
|
The FDA's major shift in September 2025 to begin publishing drug rejection letters is still an evolving process. But moving forward, the US agency should... | |
|
|
|
|
|
|
by Max Bayer
|
Encoded Therapeutics has tacked on $275 million in new capital, closing a Series F round led by GV and an undisclosed healthcare investor. The precision... | |
|
|
|
|
|
|
by Shelby Livingston
|
UpDoc, Tempus AI and Atman Health will participate in a new program that aims to build FDA-authorized agentic AI tools to care for people with... | |
|
|
|
|
|
|
by Max Bayer
|
The FDA has made permanent the leaders of CDER and CBER, stabilizing key agency posts as a new commissioner awaits confirmation. The decision was announced... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
The path to understanding a common sleep disorder started with lab banter and traveled through mice, dogs and more recently, the flu virus. Now, the... | |
|
|
|
|
|
|
by Max Bayer
|
The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. |
|
|
